Skip to content

Study · Systematic review · n = 9,533 · 2024

6 results

Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: A systematic review and multilevel meta-analysis.

Karakasis P, Patoulias D, Fragakis N, Klisic A, Rizzo M

Diabetes, obesity & metabolism20 Dec 2023Cited by 47 (Europe PMC)

PMID38116693 (opens in a new tab)DOI10.1111/dom.15410 (opens in a new tab)PepBankPUB-38116693
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, tirzepatide reduced urine albumin-to-creatinine ratio more than controls.

    In plain wordsIn adults with type 2 diabetes, tirzepatide lowered the urine albumin level more than control treatments did.

    Peptide
    Tirzepatide
    Outcome
    DecreaseUrine albumin-to-creatinine ratio
    Study

    n = 9,533

    Comparator
    Controls
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    MD
    −26.9%
    UACR

    Source sentences

    Summary
    Tirzepatide was associated with a significantly greater reduction in urine albumin-to-creatinine ratio compared with controls [mean difference (MD) -26.9%; 95% confidence interval (CI) (-34.76, -19.04); p < .001; level of evidence (LoE) moderate].
    2 context sentences
    Summary · context
    Evidence was pooled with a three-level mixed-effects meta-analysis.
    Summary · context
    In total, 9533 participants from eight RCTs were analysed.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, tirzepatide at 5, 10 and 15 mg reduced albuminuria, with a dose-response relationship.

    In plain wordsIn adults with type 2 diabetes, tirzepatide at 5, 10 and 15 mg lowered urine albumin, and higher doses had a larger effect.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAlbuminuria by tirzepatide dose
    Study

    n = 9,533

    Comparator
    Controls
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    5, 10 and 15 mgAs given in this study (human).

    Source sentences

    Summary
    The beneficial effect of tirzepatide on albuminuria levels remained significant across all investigated doses (5, 10 and 15 mg), showing a dose-response relationship.
    2 context sentences
    Summary · context
    Evidence was pooled with a three-level mixed-effects meta-analysis.
    Summary · context
    In total, 9533 participants from eight RCTs were analysed.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, tirzepatide had a neutral effect on estimated glomerular filtration rate.

    In plain wordsIn adults with type 2 diabetes, tirzepatide did not change kidney filtration rate compared with controls.

    Peptide
    Tirzepatide
    Outcome
    No significant changeEstimated glomerular filtration rate
    Study

    n = 9,533

    Comparator
    Controls
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    MD
    0.39 ml/min/1.73m2
    eGFR

    Source sentences

    Summary
    A neutral effect was observed on the estimated glomerular filtration rate [MD 0.39 ml/min/1.73m2 ; 95% CI (-0.64, 1.42); p = .46; LoE moderate].
    2 context sentences
    Summary · context
    Evidence was pooled with a three-level mixed-effects meta-analysis.
    Summary · context
    In total, 9533 participants from eight RCTs were analysed.
  4. 04HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes and baseline urine albumin-to-creatinine ratio of 30 mg/g or more, tirzepatide reduced the ratio more than controls.

    In plain wordsIn adults with type 2 diabetes and raised urine albumin, tirzepatide lowered it more than control treatments did.

    Peptide
    Tirzepatide
    Outcome
    DecreaseUrine albumin-to-creatinine ratio, baseline ratio 30 mg/g or more
    Study

    n: not reported in source

    Comparator
    Controls
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    MD
    −41.42%
    baseline UACR >=30 mg/g

    Source sentences

    Summary
    This effect remained significant in participants with baseline urine albumin-to-creatinine ratio ≥30 mg/g [MD -41.42%; 95% CI (-54.38, -28.45); p < .001; LoE moderate].
    2 context sentences
    Summary · context
    Evidence was pooled with a three-level mixed-effects meta-analysis.
    Summary · context
    In total, 9533 participants from eight RCTs were analysed.
  5. 05HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, tirzepatide reduced albuminuria more than placebo and more than an insulin regimen.

    In plain wordsIn adults with type 2 diabetes, tirzepatide lowered urine albumin more than placebo and more than insulin.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAlbuminuria versus placebo and insulin
    Study

    n: not reported in source

    Comparator
    Placebo or insulin regimen
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Based on subgroup analysis, the comparative effect of tirzepatide was significant against placebo and the insulin regimen
    2 context sentences
    Summary · context
    Evidence was pooled with a three-level mixed-effects meta-analysis.
    Summary · context
    In total, 9533 participants from eight RCTs were analysed.
  6. 06HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, tirzepatide and semaglutide did not differ in their effect on albuminuria.

    In plain wordsIn adults with type 2 diabetes, tirzepatide and semaglutide lowered urine albumin to a similar degree.

    Peptide
    Tirzepatide
    Outcome
    No significant changeAlbuminuria versus semaglutide
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    whereas no difference was observed compared with semaglutide.
    2 context sentences
    Summary · context
    Evidence was pooled with a three-level mixed-effects meta-analysis.
    Summary · context
    In total, 9533 participants from eight RCTs were analysed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.